Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
14.39
-0.11 (-0.76%)
Streaming Delayed Price
Updated: 1:12 PM EDT, Sep 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
September 17, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 08, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx (NASDAQ:RARE) Q2 Beats Estimates, Reaffirms Guidance as Shares Rise
↗
August 04, 2026
Via
Chartmill
Ultragenyx Pharma (NASDAQ:RARE) Dips After Q1 Miss as Pipeline Catalysts Loom
↗
May 05, 2026
Via
Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
September 03, 2026
Via
Chartmill
Thursday's session: top gainers and losers
↗
September 03, 2026
Via
Chartmill
Gapping stocks in Thursday's session
↗
September 03, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
September 03, 2026
Via
Chartmill
These stocks are moving in today's after hours session
↗
September 02, 2026
Via
Chartmill
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
September 02, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
September 01, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy
↗
August 20, 2026
Ultragenyx Pharmaceutical (NASDAQ:RARE) said the U.S. Food and Drug Administration has approved GENGLYCOS, also known as DTX401, for glycogen storage disease type 1A, or GSD1A. The approval marks the...
Via
MarketBeat
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
August 19, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx (RARE) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Record revenue of $214 million signals momentum ahead of gene therapy launches.
Via
The Motley Fool
Topics
Earnings
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
↗
August 04, 2026
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported second-quarter 2026 revenue of $214 million, led by growth across its commercial rare-disease portfolio, while the company prepared for potential...
Via
MarketBeat
Topics
Earnings
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
August 04, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
July 28, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
July 08, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
June 03, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
↗
May 30, 2026
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.
Via
The Motley Fool
Topics
Regulatory Compliance
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
May 06, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
May 05, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
April 29, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
